Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

795 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.
Long GV, Flaherty KT, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Chiarion-Sileni V, Lebbe C, Mandalà M, Millward M, Arance A, Bondarenko I, Haanen JBAG, Hansson J, Utikal J, Ferraresi V, Mohr P, Probachai V, Schadendorf D, Nathan P, Robert C, Ribas A, Davies MA, Lane SR, Legos JJ, Mookerjee B, Grob JJ. Long GV, et al. Among authors: garbe c. Ann Oncol. 2017 Jul 1;28(7):1631-1639. doi: 10.1093/annonc/mdx176. Ann Oncol. 2017. PMID: 28475671 Free PMC article. Clinical Trial.
Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: long-term survival and safety analysis of a phase 3 study.
Long GV, Flaherty KT, Stroyakovskiy D, Gogas H, Levchenko E, de Braud F, Larkin J, Garbe C, Jouary T, Hauschild A, Chiarion-Sileni V, Lebbe C, Mandalá M, Millward M, Arance A, Bondarenko I, Haanen JBAG, Hansson J, Utikal J, Ferraresi V, Mohr P, Probachai V, Schadendorf D, Nathan P, Robert C, Ribas A, Davies MA, Lane SR, Legos JJ, Mookerjee B, Grob JJ. Long GV, et al. Among authors: garbe c. Ann Oncol. 2019 Nov 1;30(11):1848. doi: 10.1093/annonc/mdz221. Ann Oncol. 2019. PMID: 31406976 Free PMC article. No abstract available.
Adjuvant treatment with pegylated interferon α-2a versus low-dose interferon α-2a in patients with high-risk melanoma: a randomized phase III DeCOG trial.
Eigentler TK, Gutzmer R, Hauschild A, Heinzerling L, Schadendorf D, Nashan D, Hölzle E, Kiecker F, Becker J, Sunderkötter C, Moll I, Richtig E, Pönitzsch I, Pehamberger H, Kaufmann R, Pföhler C, Vogt T, Berking C, Praxmarer M, Garbe C; Dermatologic Cooperative Oncology Group (DeCOG). Eigentler TK, et al. Among authors: garbe c. Ann Oncol. 2016 Aug;27(8):1625-32. doi: 10.1093/annonc/mdw225. Epub 2016 Jun 10. Ann Oncol. 2016. PMID: 27287206 Free article. Clinical Trial.
Vemurafenib in metastatic melanoma patients with brain metastases: an open-label, single-arm, phase 2, multicentre study.
McArthur GA, Maio M, Arance A, Nathan P, Blank C, Avril MF, Garbe C, Hauschild A, Schadendorf D, Hamid O, Fluck M, Thebeau M, Schachter J, Kefford R, Chamberlain M, Makrutzki M, Robson S, Gonzalez R, Margolin K. McArthur GA, et al. Among authors: garbe c. Ann Oncol. 2017 Mar 1;28(3):634-641. doi: 10.1093/annonc/mdw641. Ann Oncol. 2017. PMID: 27993793 Free article. Clinical Trial.
Temozolomide plus pegylated interferon alfa-2b as first-line treatment for stage IV melanoma: a multicenter phase II trial of the Dermatologic Cooperative Oncology Group (DeCOG).
Spieth K, Kaufmann R, Dummer R, Garbe C, Becker JC, Hauschild A, Tilgen W, Ugurel S, Beyeler M, Bröcker EB, Kaehler KC, Pföhler C, Gille J, Leiter U, Schadendorf D. Spieth K, et al. Among authors: garbe c. Ann Oncol. 2008 Apr;19(4):801-6. doi: 10.1093/annonc/mdm565. Epub 2008 Jan 4. Ann Oncol. 2008. PMID: 18178958 Free article. Clinical Trial.
Adjuvant low-dose interferon {alpha}2a with or without dacarbazine compared with surgery alone: a prospective-randomized phase III DeCOG trial in melanoma patients with regional lymph node metastasis.
Garbe C, Radny P, Linse R, Dummer R, Gutzmer R, Ulrich J, Stadler R, Weichenthal M, Eigentler T, Ellwanger U, Hauschild A. Garbe C, et al. Ann Oncol. 2008 Jun;19(6):1195-201. doi: 10.1093/annonc/mdn001. Epub 2008 Feb 14. Ann Oncol. 2008. PMID: 18281266 Free article. Clinical Trial.
Functional and symptom impact of trametinib versus chemotherapy in BRAF V600E advanced or metastatic melanoma: quality-of-life analyses of the METRIC study.
Schadendorf D, Amonkar MM, Milhem M, Grotzinger K, Demidov LV, Rutkowski P, Garbe C, Dummer R, Hassel JC, Wolter P, Mohr P, Trefzer U, Lefeuvre-Plesse C, Rutten A, Steven N, Ullenhag G, Sherman L, Wu FS, Patel K, Casey M, Robert C. Schadendorf D, et al. Among authors: garbe c. Ann Oncol. 2014 Mar;25(3):700-706. doi: 10.1093/annonc/mdt580. Epub 2014 Feb 6. Ann Oncol. 2014. PMID: 24504441 Free PMC article. Clinical Trial.
Sorafenib and pegylated interferon-α2b in advanced metastatic melanoma: a multicenter phase II DeCOG trial.
Egberts F, Gutzmer R, Ugurel S, Becker JC, Trefzer U, Degen A, Schenck F, Frey L, Wilhelm T, Hassel JC, Schadendorf D, Livingstone E, Mauch C, Garbe C, Berking C, Rass K, Mohr P, Kaehler KC, Weichenthal M, Hauschild A. Egberts F, et al. Among authors: garbe c. Ann Oncol. 2011 Jul;22(7):1667-1674. doi: 10.1093/annonc/mdq648. Epub 2011 Jan 10. Ann Oncol. 2011. PMID: 21220519 Free article. Clinical Trial.
795 results